This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Mar 2012

Regeneron & Bayer Confirm Austalian Clearance of Eylea

Bayer HealthCare has received Australian regulatory approval for eye drug Eylea, for the treatment of neovascular (wet) age-related macular degeneration.

Regeneron Pharmaceuticals and Bayer HealthCare announced last week that Bayer HealthCare received Australian regulatory approval for Eylea (aflibercept) injection, for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).


The approval was based on data from the Phase II View 1 and View 2 trials, which demonstrated that the drug was no less effective than more frequent injections of Lucentis (ranibizumab) in terms of maintaining visual acuity.


Eylea is currently undergoing Phase III development for wet AMD in China, and regulatory filings have been made in Euope, Japan, and other countries. The drug is in addition being evaluated in Phase III studies as a treatment for diabetic macular edema, myopic chor

Related News